

Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-60. Canceled without prejudice.

61. (Previously presented) A compound which is (-)-O-desmethylvenlafaxine succinate.

62. (Previously presented) The compound of claim 61, wherein the compound is a hydrate of (-)-O-desmethylvenlafaxine succinate.

63. (Previously presented) The compound of claim 62 which is (-)-O-desmethylvenlafaxine succinate monohydrate.

64-66. (Canceled)

67. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of (-)-O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

68. (Previously presented) A pharmaceutical dosage form comprising a therapeutically effective amount of (-)-O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

69. (Previously presented) An oral dosage form comprising a therapeutically effective amount of (-) O-desmethylvenlafaxine succinate and a pharmaceutically acceptable carrier or excipient.

70. (Previously presented) The oral dosage form of claim 69, wherein the dosage form is a tablet or capsule.

71. (Previously presented) The oral dosage form of claim 69, wherein the dosage form is a sustained release formulation.

72. (Previously presented) The oral dosage form of claim 69, further comprising a rate controlling polymer material.

73. (Previously presented) The oral dosage form of claim 72, wherein the rate controlling polymer is hydropropylmethyl cellulose.

74. (Previously presented) The oral dosage form of claim 69, wherein the oral dosage form further comprises a binder.

75. (Previously presented) The oral dosage form of claim 74, wherein the binder is microcrystalline cellulose.

76. (Previously presented) A method of treating a patient suffering from depression comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

77. (Previously presented) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 10 mg to about 1000 mg per day.

78. (Previously presented) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 50 mg to about 500 mg per day.

79. (Previously presented) A method of treating a patient suffering from depression comprising providing to a patient in need thereof (-)-O-desmethylvenlafaxine succinate in an amount of about 75 mg to about 350 mg per day.

80. (Previously presented) A method of treating a patient suffering from anxiety comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

81. (Previously presented) A method of treating a patient suffering from premenstrual dysphoric disorder comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

82. (Previously presented) A method of treating a patient suffering from a condition selected from attention deficit disorder, obsessive compulsory disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, cocaine and alcohol addiction, urinary incontinence, pain, Parkinson's disease, and epilepsy comprising providing to a patient in need thereof an effective amount of (-)-O-desmethylvenlafaxine succinate.

83. (New) A pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

84. (New) A pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine and a pharmaceutically acceptable carrier or excipient, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

85. (New) A dosage form comprising a therapeutically effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine and a pharmaceutically acceptable carrier or excipient, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

86. (New) The dosage form of claim 85, which is a tablet or a capsule.

87. (New) The dosage form of claim 85, which is adapted for intravenous infusion, transdermal delivery, or oral delivery.

88. (New) The dosage form of claim 87, wherein the therapeutically effective amount is from about 10 mg to about 1000 mg.

89. (New) The dosage form of claim 88, wherein the therapeutically effective amount is from about 50 mg to about 500 mg.

90. (New) The dosage form of claim 89, wherein the therapeutically effective amount is from about 75 mg to about 350 mg.

91. (New) A method of treating a patient suffering from depression comprising providing to a patient in need thereof an effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

92. (New) A method of treating a patient suffering from anxiety comprising providing to a patient in need thereof an effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

93. (New) A method of treating a patient suffering from premenstrual dysphoric disorder comprising providing to a patient in need thereof an effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.

94. (New) A method of treating a patient suffering from a condition selected from attention deficit disorder, obsessive compulsory disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, cocaine and alcohol addiction, urinary incontinence, pain, Parkinson's disease, and epilepsy comprising providing to a patient in need thereof an effective amount of a pharmaceutically acceptable salt of (-)-O-desmethylvenlafaxine, wherein the salt is a salt prepared from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, sulfuric, tartaric, or p-toluene sulfonic acid.